Last checked at 25 Mar 2021 07:00
SAREUM HOLDINGS PLC
("Sareum" or the "Company")
INTERIM RESULTS EXTENSION
Cambridge, UK, 25 March 2021 - Sareum Holdings plc (AIM: SAR), the specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases, advises that it will publish its interim results for the six months ended 30 December 2020, no later than 30 April 2021. The final date will be confirmed in the coming weeks.
As announced by the London Stock Exchange on 9 June 2020 and reconfirmed on 27 January 2021, AIM companies that require extra time to prepare their half-yearly reports are permitted a temporary extension of an additional one-month period, in addition to the standard three-month reporting timeframe under AIM Rule 18 of the AIM Rules for Companies. This extension is due to the continued disruption caused by the COVID-19 pandemic.
For further information, please contact:
Sareum Holdings plc Tim Mitchell, CEO
|
01223 497 700 |
Strand Hanson Limited (Nominated Adviser) James Dance / James Bellman
|
020 7409 3494 |
Hybridan LLP (Nominated Broker) Claire Noyce / John Beresford-Peirse
|
020 3764 2341 |
Citigate Dewe Rogerson (Financial PR) Mark Swallow/ David Dible |
020 7638 9571 |
About Sareum
Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.
Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the 'cytokine storm' immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802).
Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms. Preliminary Phase 2 and comprehensive preclinical data suggest SRA737 may have broad application in combination with other oncology and immune-oncology drugs in genetically defined patients.
SRA737 was discovered and initially developed by scientists at The Institute of Cancer Research in collaboration with Sareum, and with funding from Sareum and Cancer Research UK. SRA737 was licensed by CRT Pioneer Fund (CPF) to Sierra Oncology Inc. Sierra continues to explore options that would enable the development of SRA737 to advance.
Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company's website at www.sareum.com